Author Response: re - adjuvant hormone therapy in epithelial ovarian cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, March 21, 2016

Author Response: re - adjuvant hormone therapy in epithelial ovarian cancer



Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis

 

Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis

  1. Judith M. Bliss
+ Author Affiliations
  1. The Institute of Cancer Research, Sutton, London, United Kingdom
  1. Corresponding author: James P. Morden, MSc, Clinical Trials and Statistics Unit, Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, London, United Kingdom
We thank Kilickap and Tural,1 Karakas et al,2 and Voutsadakis3 for their correspondence regarding the Adjuvant Hormone Therapy (AHT) trial results in our recent article in Journal of Clinical Oncology,4 and we would like to respond to the comments raised. 

Although the correspondents are correct in their assertion that a more marked numerical difference between randomly assigned treatment groups was seen with respect to nonovarian cancer deaths (AHT, three of 75 [4%]; control, 12 of 75 [16%]) than to ovarian cancer deaths (AHT, 50 of 75 [67%]; control, 56 of 75 [75%]), we do not feel that this invalidates the most important finding of our study (ie, that if ovarian cancer treatment results in debilitating menopausal symptoms, then we do not have evidence that hormone-replacement therapy [HRT] should be withheld). We recognize that in any study of this size there is a risk of anomalous findings, but we have observed no evidence of an increase in the risk of death with HRT.
The AHT trial was initiated in 1990; as acknowledged in our discussion, there were a number of data items that would now be collected as standard in a newly initiated trial, which were not collected at the time......

 REFERENCES

  1. 1.
  2. 2.
  3. 3.

  4. 4.


  5. 5.
  6. 6.

Related Articles


0 comments :

Post a Comment

Your comments?